AMGN
Amgen Inc
Amgen Inc historical holders
total: 8
Torray Fund Amgen Inc transactions over time
- Total transactions:
- 4
- New positions:
- 1
- Added:
- 1
- Reduced:
- 2
- Held since:
- 2024 Q4
- Held for:
- 6 quarters
- Latest activity:
- 2026 Q1
Torray Fund has been an institutional investor in Amgen Inc (AMGN) since 2024 Q4. According to 2026 Q1 report, Torray Fund holds 40,000 shares with a market value of roughly $15.53M representing 4.55% of their equity portfolio. The fund/company first acquired AMGN in 2024 Q4, initially purchasing 40,660 shares. Since the initial investment, Torray Fund has made 3 more transactions in this position.
Does Torray Fund still hold AMGN?
Yes, Torray Fund continues to hold Amgen Inc (AMGN). According to their 2026 Q1 report, they maintain a position of 40,000 shares valued at approximately $15.53M, representing 4.55% of their equity portfolio.
When did Torray Fund first invest in AMGN?
Torray Fund first invested in Amgen Inc (AMGN) in 2024 Q4 at the reported quarter-end price of $282.87 per share, acquiring 40,660 shares in their initial purchase.
What is Torray Fund's average cost basis for AMGN?
Based on historical transaction data, Torray Fund's estimated cost basis for Amgen Inc (AMGN) is approximately $284.02 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $284.02
- Weighted AVG sell price:
- $363.49
AMGN transactions history by Torray Fund
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
4.55%
|
40,000
|
$388.16
|
$15,526,400
|
-11.11% (-5,000)
|
-0.54%
|
|
2025 Q4
|
4.35%
|
45,000
|
$345.46
|
$15,545,700
|
-13.19% (-6,840)
|
-0.65%
|
|
2025 Q2
|
4.51%
|
51,840
|
$288.18
|
$14,939,251
|
+27.50% (+11,180)
|
+0.97%
|
|
2024 Q4
|
3.19%
|
40,660
|
$282.87
|
$11,501,494
|
new
|
+3.19%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.